Brightgene Bio-medical Technology Co. Ltd. Class ASSE: 688166

"BrightGene Bio-Medical Technology Co., Ltd."Semi-annual Report for 2026

Aug 31, 2026 · Issued by Brightgene Bio-medical Technology Co. Ltd. Class A via Shanghai Stock Exchange

Semi-annual Report for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Brightgene Bio-medical Technology Co. Ltd. Class A

"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss IndicationAug 7
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide Inhalation Spray by a Controlled SubsidiaryAug 1
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide and Olodaterol Inhalation Spray by a Controlled SubsidiaryJul 25
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on the Board Secretary's Obtaining the Certificate of Qualification Training and Officially Assuming DutiesJul 24

All Brightgene Bio-medical Technology Co. Ltd. Class A news releases